The Week In Review: Profit potential in university graduates

The London stock market is carving itself a niche as a first-choice fund-raising centre for 'technology transfer' companies, outfits that exist to help universities and academics, companies and inventors to commercialise their innovations.

After a flurry of floats this year, there is now a cluster of about 10 of these companies, though not all look long-term winners. The theory is that academic institutions have a poor record of exploiting intellectual property, and there is a commercial opportunity in helping them. The technology transfer company's investors get access to a diverse range of new inventions. It's a numbers game, they say. Sooner or later, one of the technologies will turn out to be a blockbuster.

Except there is little evidence that the numbers stack up. The longer a technology transfer company has been around, the worse its track record appears to be. BTG and Generics, which both employ dozens of scientists to turn patents into products, are the classic examples.

One model that does look appealing is that of Utek Corporation, floated here in April but on Nasdaq since 2000. It has taken most of the risk out by allying itself not with inventors but with corporate product developers. It works on contract to them to scan the universities of the UK, Europe, Israel and North America for technologies they need for an urgent project, and typically makes a five-times mark-up on buying the technology and selling it on. Buy.

Mears Group

Investors who bought into Mears Group at its flotation have made their money 25 times over. Mears paints council houses, mends leaky taps, fixes broken windows or does a spot of rewiring. There is about £5bn of such work out there each year, and Mears has grown because more councils have brought in the private sector. Even so, this is not high-margin work, and should not command a sky-high stock market rating. Improved dividend and upgraded earnings forecasts this week will help, but the shares are too high.

Pinewood Shepperton

Sir Michael Grade, the chairman of the BBC governors, also chairs Pinewood Shepperton, the British film studios business that is desperate to attract more TV production work from programme makers such as, er, the BBC. This happy coincidence will help Pinewood, but it doesn't justify investing in this high-risk company. A year after a flotation aimed at paying down debt, Pinewood has had to agree a new overdraft to avoid breaching banking covenants. Sell.

Ark Therapeutics

To many in the City, Ark represents the last flotation for Old Biotech, gotten away after a big marketing push by its brokers in March 2004 but never having seen the issue price since. Most of the value in Ark, which is currently heavily loss making, lies in hopes for Cerepro, a live virus injected into the brain that seems to prolong the life of people who have had a tumour out. It could be on sale in Europe in 2007, but it is new science and risky. Ark has a long list of milestones it could pass in the coming months, all of which could move the shares up in the short term. But for the long term, sell


Whitbread shares have more than doubled over the past five years but looking at its latest trading statement it is hard to see why. Everything the group does is either at a standstill or going backwards with one exception - its Premier Travel Inn budget hotels. Put simply Whitbread is a conglomerate throwback and it needs to focus. A break-up is now the only thing that justifies a share price of 978p. Sell

Avis Europe

It all went wrong at once for Avis Europe, the hire car business. US visitors to the UK fell away after the 11 September attacks. The European economy has failed to manage anything other than sluggish growth and corporate customers have kept belts tight. Profits went downhill faster than a hire car with the handbrake off, and Avis was forced into a £110m rights issue this summer. Since then, there have been signs of improvement, but the shares already factor in a recovery and a little bid speculation. Avoid.


Axis-Shield's 2001 splurge on research and development looks like paying off. In both its diagnostics and laboratory divisions, it has new products about to come to market. Both are promising and we missed a trick by advising investors to hold off in 2003. Still, Axis-Shield is at a tricky inflexion point, back in the black but looking pricey given the modest profits expected while the new products are rolled out. With regret, still pass.

The above are recommendations taken from the daily Investment Column.

Independent Partners; Do you need financial advice on your investments, pension or insurance? Book a free consultation with an independent Financial Adviser at

Finacial products from our partners
Property search
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    SThree: Talent Acquisition Consultant

    £22500 - £27000 per annum + OTE £45K: SThree: Since our inception in 1986, STh...

    Recruitment Genius: Experienced Financial Advisers and Paraplanners

    Negotiable: Recruitment Genius: This extremely successful and well-established...

    Guru Careers: FX Trader / Risk Manager

    Competitive with monthly bonus: Guru Careers: We are seeking an experienced FX...

    Guru Careers: Investment Writer / Stock Picker

    Competitive (Freelance) : Guru Careers: An Investment Writer / Stock Picker is...

    Day In a Page

    How to stop an asteroid hitting Earth: Would people co-operate to face down a global peril?

    How to stop an asteroid hitting Earth

    Would people cooperate to face a global peril?
    Just one day to find €1.6bn: Greece edges nearer euro exit

    One day to find €1.6bn

    Greece is edging inexorably towards an exit from the euro
    New 'Iron Man' augmented reality technology could help surgeons and firefighters, say scientists

    'Iron Man' augmented reality technology could become reality

    Holographic projections would provide extra information on objects in a person's visual field in real time
    Sugary drinks 'are killing 184,000 adults around the world every year'

    Sugary drinks are killing 184,000 adults around the world every year

    The drinks that should be eliminated from people's diets
    Pride of Place: Historians map out untold LGBT histories of locations throughout UK

    Historians map out untold LGBT histories

    Public are being asked to help improve the map
    Lionel, Patti, Burt and The Who rock Glasto

    Lionel, Patti, Burt and The Who rock Glasto

    This was the year of 24-carat Golden Oldies
    Paris Fashion Week

    Paris Fashion Week

    Thom Browne's scarecrows offer a rare beacon in commercial offerings
    A year of the caliphate:

    Isis, a year of the caliphate

    Who can defeat the so-called 'Islamic State' – and how?
    Marks and Spencer: Can a new team of designers put the spark back into the high-street brand?

    Marks and Spencer

    Can a new team of designers put the spark back into the high-street brand?
    'We haven't invaded France': Italy's Prime Minister 'reclaims' Europe's highest peak

    'We haven't invaded France'

    Italy's Prime Minister 'reclaims' Europe's highest peak
    Isis in Kobani: Why we ignore the worst of the massacres

    Why do we ignore the worst of the massacres?

    The West’s determination not to offend its Sunni allies helps Isis and puts us all at risk, says Patrick Cockburn
    7/7 bombings 10 years on: Four emergency workers who saved lives recall the shocking day that 52 people were killed

    Remembering 7/7 ten years on

    Four emergency workers recall their memories of that day – and reveal how it's affected them ever since
    Humans: Are the scientists developing robots in danger of replicating the hit Channel 4 drama?

    They’re here to help

    We want robots to do our drudge work, and to look enough like us for comfort. But are the scientists developing artificial intelligence in danger of replicating the TV drama Humans?
    Time to lay these myths about the Deep South to rest

    Time to lay these myths about the Deep South to rest

    'Heritage' is a loaded word in the Dixie, but the Charleston killings show how dangerous it is to cling to a deadly past, says Rupert Cornwell
    What exactly does 'one' mean? Court of Appeal passes judgement on thorny mathematical issue

    What exactly does 'one' mean?

    Court of Appeal passes judgement on thorny mathematical issue